Recent & Archived News
August 13, 2019
JIVI® (antihemophilic factor [recombinant] PEGylated-aucl) Pharmacokinetic Profile Compared to Eloctate® Showed Improved Characteristics in PK Study of Extended Half-life Recombinant FVIII Therapies
A head-to-head study directly comparing the pharmacokinetic (PK) profiles of two extended half-life (EHL) recombinant factor VIII (FVIII) therapies demonstrated improved PK characteristics for...
August 08, 2019
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on...
August 06, 2019
Bayer Awards $1.5 Million Grant To BioSTL To Support Organization's Headquarters And Program Expansion In St. Louis' Emerging Technology District
Bayer has awarded BioSTL, a St. Louis-based non-profit which advances and promotes the region's growing bioscience, innovation and technology community, a $1.5 million grant to support its new...
August 01, 2019
Bayer Extends Multi-Year Partnership with Luke Bryan and its Commitment to its Here's to the Farmer Campaign
After donating close to 3 million meals across the United States, Bayer reaffirmed its partnership and commitment to its Here's to the Farmer campaign with Luke Bryan. Bayer will join the country...
July 30, 2019
FDA approves Bayer's Nubeqa® (darolutamide), a new treatment for men with non-metastatic castration-resistant prostate cancer
The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant...
July 24, 2019
Bayer Consumer Health and White Ribbon Alliance Announce Three-Year Renewal of Partnership to Improve the Every Day Health of Women, Infants and Children through Self-Care
Bayer and White Ribbon Alliance today announced they will extend their partnership and expand their initiative to help women in low and middle income countries gain the knowledge and confidence...
July 22, 2019
Daily Aspirin Still Recommended for Millions of Americans Who Have Had a Heart Attack or Ischemic Stroke
In response to the report in today's Annals of Internal Medicine, Bayer realizes there may be confusion around the appropriate use of aspirin, which in the United States is only approved for...
July 22, 2019
Bayer Earns Top Marks in 2019 Disability Equality Index
For the first time, Bayer U.S. earned an 80 in the 2019 Disability Equality Index (DEI), and was recognized as a Best Place to Work for Disability Inclusion. DEI is the most comprehensive...
July 19, 2019
Bayer statement on voluntary recall of two lots of Kogenate® FS antihemophilic factor (recombinant) in the United States
Bayer is voluntarily recalling two lots of Kogenate® FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level. Certain vials from these two lots that were...
July 18, 2019
Bayer Partners with the National Press Foundation to Provide Educational Training Programs for Journalists
As part of its longstanding partnership with the National Press Foundation (NPF), Bayer announced today its sponsorship of two educational programs focused on agriculture and cardiovascular...
Want even more Bayer news?
Last Updated: December 14, 2018